<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10891">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00618332</url>
  </required_header>
  <id_info>
    <org_study_id>15624B</org_study_id>
    <nct_id>NCT00618332</nct_id>
  </id_info>
  <brief_title>Can a Nasal Decongestant Test Predict Treatment Outcomes in Seasonal Allergic Rhinitis?</brief_title>
  <official_title>Does the Response to a Nasal Decongestant Test Predict the Outcome to Treatment of Seasonal Allergic Rhinitis With Nasonex?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesize that those patients with purely seasonal allergic rhinitis will decongest
      better than those subjects with another cause contributing to their symptoms. These latter
      patients will not improve as well on an intranasal steroid as those who decongest well,
      potentially explaining the 60% response rate in prior studies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)</study_design>
  <primary_outcome>
    <measure>Global Assessment</measure>
    <time_frame>at week 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>Global Assessment: 3=significantly improved, 2=moderately improved,
1=mildly improved, 0=no change, -1=mildly worse, -2=moderately worse, and -3=significantly worse</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in RQLQ: Overall</measure>
    <time_frame>Baseline and 2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The RQLQ is a disease-specific measure of a patient's quality of life. It includes domains that measure nasal and eye symptoms as well as those of activity, sleep, non-nasal/eye symptoms, practical and emotional measures. A scale of 0-6 is used to record the patient responses, with lower scores reflecting a better quality of life. The average score of each domain is calculated as well as an overall domain score reflecting the average of all scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in RQLQ: Activity</measure>
    <time_frame>Baseline and 2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The RQLQ activity range: 0-6. Higher scores indicate a worse quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in RQLQ: Sleep</measure>
    <time_frame>Baseline and 2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The RQLQ sleep range: 0-6. Higher scores indicate a worse quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in RQLQ: Non-Nasal/Eye</measure>
    <time_frame>Baseline and 2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The RQLQ non-nasal/eye range: 0-6. Higher scores indicate a worse quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in RQLQ: Practical</measure>
    <time_frame>Baseline and 2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The RQLQ practical range: 0-6. Higher scores indicate a worse quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in RQLQ: Nasal</measure>
    <time_frame>Baseline and 2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The RQLQ nasal range: 0-6. Higher scores indicate a worse quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in RQLQ: Emotional</measure>
    <time_frame>Baseline and 2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The RQLQ emotional range: 0-6. Higher scores indicate a worse quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in RQLQ: Eye</measure>
    <time_frame>Baseline and 2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The RQLQ eye range: 0-6. Higher scores indicate a worse quality of life.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 weeks of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 weeks of treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mometasone furoate nasal spray</intervention_name>
    <description>2 puffs in each nostril once a day for 2 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Nasonex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>2 puffs in each nostril once a day for 2 weeks</description>
    <arm_group_label>2</arm_group_label>
    <other_name>placebo comparator for Nasonex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Males and females between 18 and 60 years of age.

          2. History of grass and/or ragweed allergic rhinitis.

          3. Positive skin or RAST test to grass, trees and/or ragweed antigen.

          4. Symptomatic at time of entry into study.

        Exclusion Criteria

          1. Women of childbearing potential not using the contraception method(s) (Birth control
             pills, depo Provera, double barrier) as well as women who are pregnant or
             breastfeeding.

          2. Patients with severe medical condition(s) that in the view of the investigator
             prohibits participation in the study (heart, lung, kidney, neurological, oncologic or
             liver disease).

          3. Use of any other investigational agent in the last 30 days.

          4. Absence of nasal symptoms.

          5. Smoking.

          6. URI at the time of screening.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert M Naclerio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 21, 2014</lastchanged_date>
  <firstreceived_date>February 6, 2008</firstreceived_date>
  <firstreceived_results_date>November 21, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mometasone furoate</mesh_term>
    <mesh_term>Nasal Decongestants</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mometasone Furoate</title>
          <description>2 weeks of treatment
mometasone furoate nasal spray : 2 puffs in each nostril once a day for 2 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>2 weeks of treatment
placebo : 2 puffs in each nostril once a day for 2 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mometasone Furoate</title>
          <description>2 weeks of treatment
mometasone furoate nasal spray : 2 puffs in each nostril once a day for 2 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>2 weeks of treatment
placebo : 2 puffs in each nostril once a day for 2 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="32.6" spread="9.36"/>
                <measurement group_id="B2" value="35" spread="12"/>
                <measurement group_id="B3" value="33.8" spread="10.98"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="16"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="24"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Global Assessment</title>
        <description>Global Assessment: 3=significantly improved, 2=moderately improved,
1=mildly improved, 0=no change, -1=mildly worse, -2=moderately worse, and -3=significantly worse</description>
        <time_frame>at week 2</time_frame>
        <safety_issue>No</safety_issue>
        <population>There were one patient in the Mometasone Furoate group and two patients in the Placebo group with missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate</title>
            <description>2 weeks of treatment
mometasone furoate nasal spray : 2 puffs in each nostril once a day for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 weeks of treatment
placebo : 2 puffs in each nostril once a day for 2 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Global Assessment</title>
            <description>Global Assessment: 3=significantly improved, 2=moderately improved,
1=mildly improved, 0=no change, -1=mildly worse, -2=moderately worse, and -3=significantly worse</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.7" spread="1.1" lower_limit="0" upper_limit="3"/>
                  <measurement group_id="O2" value="1.4" spread="1.2" lower_limit="-1" upper_limit="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.372</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in RQLQ: Overall</title>
        <description>The RQLQ is a disease-specific measure of a patient’s quality of life. It includes domains that measure nasal and eye symptoms as well as those of activity, sleep, non-nasal/eye symptoms, practical and emotional measures. A scale of 0–6 is used to record the patient responses, with lower scores reflecting a better quality of life. The average score of each domain is calculated as well as an overall domain score reflecting the average of all scores.</description>
        <time_frame>Baseline and 2 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate</title>
            <description>2 weeks of treatment
mometasone furoate nasal spray : 2 puffs in each nostril once a day for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 weeks of treatment
placebo : 2 puffs in each nostril once a day for 2 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Changes in RQLQ: Overall</title>
            <description>The RQLQ is a disease-specific measure of a patient’s quality of life. It includes domains that measure nasal and eye symptoms as well as those of activity, sleep, non-nasal/eye symptoms, practical and emotional measures. A scale of 0–6 is used to record the patient responses, with lower scores reflecting a better quality of life. The average score of each domain is calculated as well as an overall domain score reflecting the average of all scores.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-1.35" spread="1.09"/>
                  <measurement group_id="O2" value="-1.25" spread="1.09"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.775</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in RQLQ: Activity</title>
        <description>The RQLQ activity range: 0–6. Higher scores indicate a worse quality of life.</description>
        <time_frame>Baseline and 2 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate</title>
            <description>2 weeks of treatment
mometasone furoate nasal spray : 2 puffs in each nostril once a day for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 weeks of treatment
placebo : 2 puffs in each nostril once a day for 2 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Changes in RQLQ: Activity</title>
            <description>The RQLQ activity range: 0–6. Higher scores indicate a worse quality of life.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-1.73" spread="1.64"/>
                  <measurement group_id="O2" value="-1.55" spread="1.78"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.737</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in RQLQ: Sleep</title>
        <description>The RQLQ sleep range: 0–6. Higher scores indicate a worse quality of life.</description>
        <time_frame>Baseline and 2 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate</title>
            <description>2 weeks of treatment
mometasone furoate nasal spray : 2 puffs in each nostril once a day for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 weeks of treatment
placebo : 2 puffs in each nostril once a day for 2 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Changes in RQLQ: Sleep</title>
            <description>The RQLQ sleep range: 0–6. Higher scores indicate a worse quality of life.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-1.42" spread="1.18"/>
                  <measurement group_id="O2" value="-0.85" spread="1.05"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.117</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in RQLQ: Non-Nasal/Eye</title>
        <description>The RQLQ non-nasal/eye range: 0–6. Higher scores indicate a worse quality of life.</description>
        <time_frame>Baseline and 2 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate</title>
            <description>2 weeks of treatment
mometasone furoate nasal spray : 2 puffs in each nostril once a day for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 weeks of treatment
placebo : 2 puffs in each nostril once a day for 2 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Changes in RQLQ: Non-Nasal/Eye</title>
            <description>The RQLQ non-nasal/eye range: 0–6. Higher scores indicate a worse quality of life.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-1.11" spread="1.05"/>
                  <measurement group_id="O2" value="-1.26" spread="1.22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.676</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in RQLQ: Practical</title>
        <description>The RQLQ practical range: 0–6. Higher scores indicate a worse quality of life.</description>
        <time_frame>Baseline and 2 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate</title>
            <description>2 weeks of treatment
mometasone furoate nasal spray : 2 puffs in each nostril once a day for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 weeks of treatment
placebo : 2 puffs in each nostril once a day for 2 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Changes in RQLQ: Practical</title>
            <description>The RQLQ practical range: 0–6. Higher scores indicate a worse quality of life.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-1.37" spread="1.26"/>
                  <measurement group_id="O2" value="-1.48" spread="1.54"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.795</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in RQLQ: Nasal</title>
        <description>The RQLQ nasal range: 0–6. Higher scores indicate a worse quality of life.</description>
        <time_frame>Baseline and 2 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate</title>
            <description>2 weeks of treatment
mometasone furoate nasal spray : 2 puffs in each nostril once a day for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 weeks of treatment
placebo : 2 puffs in each nostril once a day for 2 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Changes in RQLQ: Nasal</title>
            <description>The RQLQ nasal range: 0–6. Higher scores indicate a worse quality of life.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-1.54" spread="1.47"/>
                  <measurement group_id="O2" value="-1.31" spread="1.53"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.638</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in RQLQ: Emotional</title>
        <description>The RQLQ emotional range: 0–6. Higher scores indicate a worse quality of life.</description>
        <time_frame>Baseline and 2 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>There were one patient in the Mometasone Furoate group with a missing value.</population>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate</title>
            <description>2 weeks of treatment
mometasone furoate nasal spray : 2 puffs in each nostril once a day for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 weeks of treatment
placebo : 2 puffs in each nostril once a day for 2 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Changes in RQLQ: Emotional</title>
            <description>The RQLQ emotional range: 0–6. Higher scores indicate a worse quality of life.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-1.05" spread="1.57"/>
                  <measurement group_id="O2" value="-0.94" spread="1.24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.800</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in RQLQ: Eye</title>
        <description>The RQLQ eye range: 0–6. Higher scores indicate a worse quality of life.</description>
        <time_frame>Baseline and 2 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate</title>
            <description>2 weeks of treatment
mometasone furoate nasal spray : 2 puffs in each nostril once a day for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 weeks of treatment
placebo : 2 puffs in each nostril once a day for 2 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Changes in RQLQ: Eye</title>
            <description>The RQLQ eye range: 0–6. Higher scores indicate a worse quality of life.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-1.36" spread="1.41"/>
                  <measurement group_id="O2" value="-1.34" spread="1.32"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.968</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Mometasone Furoate</title>
          <description>2 weeks of treatment
mometasone furoate nasal spray : 2 puffs in each nostril once a day for 2 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>2 weeks of treatment
placebo : 2 puffs in each nostril once a day for 2 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Robert Naclerio</name_or_title>
      <organization>University of Chicago</organization>
      <phone>773-702-0080</phone>
      <email>rnacleri@surgery.bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
